Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2014 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (295)	4/22/2014 12:31:57 PM
From: Biotech Jim	Read Replies (1) \| Respond to of 487

After reading the past few posts with your initiating idea, Rick, I was going to post on EPZM. I do like their lead program/compound, DOT1L and EPZ-5676. Nice collaborations here along with decent results to date. I also know the CEO and think he has been a great fit, and has extensive pharma experience formerly at MRK. I will mention several additional ideas, as these were good picks at least a week ago. Most have had significant bounces. RIGL, ACAD, INCY, MDVN as well as the above mentioned EPZM and your mention of MGNX. I like the basket approach with these.